We tested here the prediction that marked NMO pathology might be produced in the central nervous system by passive transfer of AQP4-IgG to CD59−/− rats, without added complement, under conditions where minimal pathology is produced in CD59+/+ rats. This evidence concerns the gene CD59 and neuromyelitis optica.